CGEM — Cullinan Therapeutics Share News
0.000.00%
Last trade - 00:00- $960.17m
- $625.63m
Brief: Cullinan Therapeutics- Cullinan Amber Notified MIT Decision To Terminate Exclusive Patent License Agreement For Cln-617
Brief: Taiho Oncology, Taiho Pharmaceutical And Cullinan Therapeutics initiate rolling submission of new drug application to US FDA
Cullinan Therapeutics' Q3 net loss widens
Brief: Cullinan Therapeutics Q3 Operating Expenses USD 55.595 Million
Cullinan Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cullinan Therapeutics Q2 Operating Expenses USD 75.798 Million
Brief: Cullinan Therapeutics Licenses Rights to Velinotamig
Brief: Cullinan Therapeutics Inc - Taiho Oncology And Cullinan Therapeutics Publish Positive Rezilient1 Trial Results
Cullinan Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Cullinan Therapeutics Q1 Net Income USD -48.501 Million
Brief: Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the USA
Brief: Cullinan Therapeutics Receives Approval From European Medicines Agency To Initiate Phase 1 Trial Of Cln-978
U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix
Cullinan Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Cullinan Therapeutics Provides Corporate Update And Reports Q3 2024 Financial Results
Brief: Cullinan Oncology Q3 Net Income USD -40.56 Million
Cullinan Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Cullinan Therapeutics Receives U.S. FDA Clearance Of Investigational New Drug Application For CLN-978 Administered Subcutaneously In Patients With Moderate To Severe Systemic Lupus Erythematosus
Brief: Cullinan Therapeutics Announces Submission Of Investigational New Drug Application To U.S. Food And Drug Administration For Cln-978 To Treat Systemic Lupus Erythematosus